A major clinical trial has revealed disappointing results for setmelanotide, a promising obesity treatment, when used in patients carrying single genetic mutations associated with weight gain. The EMANATE trial, conducted by Rhythm Pharmaceuticals, tested the melanocortin-4 receptor agonist in four distinct patient populations, each carrying a different heterozygous genetic variant linked to obesity. The results, reported by Healio.com, suggest that the drug’s mechanism of action may be insufficient for patients who carry only one mutated copy of obesity-related genes.
The trial enrolled patients with heterozygous variants in four key genes: POMC/PCSK1, LEPR, SRC1, and SH2B1. These genes play crucial roles in the melanocortin pathway, which regulates hunger and energy expenditure. In a randomized, double-blind, placebo-controlled design, participants received either setmelanotide or placebo for one year. The results across all four substudies failed to demonstrate statistically significant BMI reductions when comparing setmelanotide to placebo. Placebo-adjusted BMI changes ranged from just 1.7% for SH2B1 carriers to 4.3% for POMC/PCSK1 carriers—improvements that fell short of statistical significance thresholds required for regulatory approval.
The findings represent a significant setback for Rhythm Pharmaceuticals, particularly given setmelanotide’s existing FDA approvals. The drug was previously approved for homozygous deficiencies in POMC, PCSK1, and LEPR in 2020, with Bardet-Biedl syndrome approval following in 2022. These approvals were based on patients carrying two mutated copies of disease-related genes. The distinction is critical: homozygous mutations completely eliminate gene function, whereas heterozygous mutations impair it only partially. The EMANATE results suggest that partial genetic impairment may not respond adequately to setmelanotide’s mechanism.
However, the trial wasn’t entirely without encouraging signals. Post hoc analyses—secondary examinations of the data conducted after the trial—revealed more promising results in certain subgroups. Among patients with POMC/PCSK1 variants, those receiving setmelanotide experienced a 5.5% greater BMI decline than placebo controls, and this result reached statistical significance. Similarly, patients with SRC1 variants showed a 6.2% greater BMI reduction with the drug. When researchers examined only participants who completed the full year of treatment, the differences became even more pronounced, with POMC/PCSK1 carriers showing a 9.7% greater decline and SRC1 carriers experiencing an 8% greater decrease.
These secondary findings have encouraged the pharmaceutical company to continue investigating the drug’s potential. Rhythm Pharmaceuticals indicated plans to conduct further analysis of the EMANATE data and to pursue development of next-generation melanocortin-4 receptor agonists specifically targeting heterozygous POMC/PCSK1 and SRC1 variants.
Safety remained consistent with previous setmelanotide trials, with no unexpected adverse events reported. Common side effects included skin hyperpigmentation, injection site reactions, nausea, vomiting, and headaches.
The trial underscores an important principle in rare disease medicine: genetic heterogeneity requires tailored therapeutic approaches. While setmelanotide proved transformative for patients with complete genetic defects, the heterozygous populations studied appear to need either higher doses, extended treatment periods, or fundamentally different pharmacological approaches to achieve meaningful weight loss benefits.
